Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 27, 2021
FDA Grants Orphan Drug Designation to Aerami Therapeutics’s Imatinib
Author(s)Pharmaceutical Technology Editors
FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.
Advertisement
Aerami Therapeutics—a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases—announced in an Aug. 25, 2021 press release that FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension (PAH). AER-901 is Aerami’s drug-device combination product candidate for inhaled imatinib for the treatment of PAH. It is currently in a Phase I trial that is estimated to be completed toward the end of 2021.
“Receiving orphan drug designation for imatinib in AER-901 is another important milestone to emerge from our PAH development program,” said Steve Thornton, CEO of Aerami, in a press release. “We are pleased with the progress we are making in our Phase I trial and believe that AER-901, which is targeted to enter Phase II/III trials in the first half of 2022, might, for the first time, provide the opportunity to modify the course of this terrible disease, and offer an important therapeutic option for patients.”
Although there aren’t many patients with PAH and the approved drugs don’t fundamentally modify or halt the progression of the disease, the global market for PAH treatments is an estimated $5.5 billion in worldwide sales in 2020, according to the company press release.
Source:
Advertisement
Related to this article
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Advertisement
Advertisement